Tech Company Financing Transactions

Naurex Funding Round

Baxter Ventures, Adams Street Partners and Druid Bioventures participated in a $38 million Series B funding round for Naurex. The funding round was announced on 12/17/2012.

Transaction Overview

Company Name
Naurex
Announced On
12/17/2012
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series B
Investors

Baxter Ventures (Lead Investor) (Norbert Riedel)

Adams Street Partners (Terry Gould)

Druid Bioventures

Genesys Capital

Latterell Venture Partners (Kenneth Widder)

Lundbeckfond Ventures

PathoCapital

Shire Pharmaceuticals

Takeda Ventures

Proceeds Purpose
Naurex will use the proceeds from the Series B financing to fund a number of key programs from its NMDA receptor modulator platform, including conducting a Phase Ilb trial of GLYX-13, the company's lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and further developing its second- and third-generation programs for other CNS disorders.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1801 Maple Ave. 4300
Evanston, IL 60201
USA
Phone
(847) 871-0377
Website
www.naurex.com
Email Address
[email protected]
Overview
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
Profile
Naurex LinkedIn Company Profile
Social Media
Naurex Company Twitter Account
Company News
Naurex News
Facebook
Naurex on Facebook
YouTube
Naurex on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Norbert Riedel
  Norbert Riedel LinkedIn Profile  Norbert Riedel Twitter Account  Norbert Riedel News  Norbert Riedel on Facebook
Chief Financial Officer
James Schulz
  James Schulz LinkedIn Profile  James Schulz Twitter Account  James Schulz News  James Schulz on Facebook
Chief Medical Officer
Ronald Burch
  Ronald Burch LinkedIn Profile  Ronald Burch Twitter Account  Ronald Burch News  Ronald Burch on Facebook
Chief Scientific Officer
Joseph Moskal
  Joseph Moskal LinkedIn Profile  Joseph Moskal Twitter Account  Joseph Moskal News  Joseph Moskal on Facebook
VP - Bus. Development
Ashish Khanna
  Ashish Khanna LinkedIn Profile  Ashish Khanna Twitter Account  Ashish Khanna News  Ashish Khanna on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/15/2012: Nara Logics venture capital transaction
Next: 12/17/2012: LaunchKey venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.